From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
October 22, 2018
Philadelphia, PA, October 22, 2018 – IntegriChain, a leading life sciences commercial analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation and adherence, today announced that its annual IntegriChain User Conference, beginning today in Savannah, broke attendance records with more than 160 participants, including seven IntegriChain ecosystem partners and nearly 20 industry speakers. The three-day conference attracts bio/pharma brand and access teams, including those focused on Managed Markets, Patient Services, Finance, and Trade, from leading and emerging manufacturers. The IntegriChain User Conference begins today with an Executive Summit, delivering thought leadership and high-value presentations focused on strategies to drive pharmaceutical access. Beginning on Day 2, IntegriChain delivers industry panels, benchmark reports, and dozens of topic track sessions focused on overcoming strategic commercialization challenges, uncovering business intelligence insights through data-driven analytics, and hands-on ICyte Platform functionality.
“The growth and success of the IntegriChain User Conference is a testament to IntegriChain’s unique alignment with the operational and insights challenges faced by bio/pharma commercial teams,” said Kevin Leininger, Co-Founder and CEO of IntegriChain. “Our mission is to help all the stakeholders in bio/pharma access save as many patient therapy days as possible. Our data and analytics help commercial teams find patients who forgo therapy and help them get patients on therapy faster and longer. For bio/pharma brand teams, the ability to save patient therapy days is immensely valuable–it improves outcomes and drives brand success. We thank all our customers for joining us this week in Savannah and for forging a deep and meaningful partnership to help patients start and stay on therapy. We also thank our ecosystem partners for supporting our conference and delivering an expanded set of access insights to our customers.”
The keynote speaker of the IntegriChain User Conference ‘18 is industry expert Dr. Adam J. Fein, CEO of the Drug Channels Institute and one of the country’s foremost experts on pharmaceutical economics and channel strategy. Dr. Fein will provide his views on “Winning Strategies for Integrated Drug Channels,” addressing the integration challenges facing bio/pharma manufacturers.
The IntegriChain User Conference ‘18 is supported by the following IntegriChain Ecosystem Partners: Alpha 1C, AssistRx, ICON, Loopback Analytics, PPi Healthcare Consulting, VMS BioMarketing, and WDSrx.
IntegriChain is a life sciences commercial analytics company that helps innovative bio/pharma manufacturers identify and remove barriers to patient therapy initiation and adherence. Our ICyte Platform and solutions uniquely focus on what happens after the patient and provider commit to therapy. More than 140 life science manufacturers rely on insights delivered from IntegriChain’s data, analytics, and managed services to drive strategic decision-making and on-going business management across their payers, specialty pharmacies, patient services, and distribution channel partners. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA; the Access Management Operations center is in Ambler, PA; and the Patient Services Center is in Atlanta, GA. For more information, visit www.integrichain.com or follow us on Twitter @IntegriChain and LinkedIn.
Contact Jennifer Guinan | Sage Strategic Marketing | 610.410.8111 | Jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List
